Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies (Tables)

v3.21.4
Summary of Significant Accounting Policies (Tables)
12 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Disaggregation of Revenue
Disaggregated revenue by product line was as follows:

For the Years Ended
September 30,
2021 2020 2019
Product Line(1):
Short Distance
$ 22,253  $ 9,466  $ 26,040 
MediMobility Organ Transport and Jet
26,346  13,476  5,071 
Other
1,927  492  85 
Total Revenue
$ 50,526  $ 23,434  $ 31,196 
__________
(1) Prior period amounts have been updated to conform to current period presentation.
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
For the years ended September 30, 2021, 2020 and 2019, the following outstanding common stock equivalents have been excluded from the calculation of net loss per share because their impact would be anti-dilutive.

As of September 30,
2021 2020 2019
Warrants to purchase shares of common stock
14,166,666  —  — 
Options to purchase shares of common stock
8,978,185  9,859,674  8,575,335 
Restricted shares of common stock
2,137,132  —  — 
Total potentially dilutive securities
25,281,983  9,859,674  8,575,335 
Property, Plant and Equipment
As of September 30,
Useful Life
(in years)
2021

2020
Furniture and fixtures
5 $ 497  $ 437 
Technology equipment
3 282  182 
Leasehold improvements Shorter of useful life or life of lease 2,380  2,215 
Vehicles 5 239 
Total property and equipment, gross 3,398  2,839 
Less: Accumulated depreciation and amortization (1,440) (1,080)
Total property and equipment, net $ 1,958  $ 1,759 
Contract with Customer, Contract Asset, Contract Liability, and Receivable The table below presents a roll forward of the contract liability balance:

For the Years Ended
September 30,
2021 2020
Balance, beginning of period
$ 3,973  $ 3,328 
Additions 50,301  23,792 
Revenue recognized
(49,620) (23,147)
Balance, end of period
$ 4,654  $ 3,973